Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 19/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445690 | 0.72 | TYMP (0.56) | TYMP | |
| SCHEMBL28448729 | 0.72 | TYMP (0.56) | TYMP | |
| SCHEMBL31376425 | 0.70 | TYMP (0.54) | TYMP | |
| SCHEMBL6570508 | 0.69 | TYMP (0.46) | TYMP | |
| SCHEMBL7540892 | 0.69 | TYMP (0.70) | TYMP | |
| SCHEMBL1484455 | 0.69 | TYMP (0.45) | TYMP | |
| SCHEMBL17524430 | 0.68 | TYMP (0.52) | TYMP | |
| SCHEMBL1228773 | 0.68 | TYMP (1.00) | TYMP | |
| SCHEMBL2888237 | 0.68 | TYMP (0.52) | TYMP | |
| SCHEMBL4561126 | 0.68 | TYMP (0.52) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110437161-A | A kind of preparation method of 5- methyl -6- chlorouracil | UNIV DALIAN | 2019-11-12 | — | — | CN | claimed |
| US-20240343737-A1 | Imaging Agents | UCB Biopharma SRL (BE) | 2024-10-17 | — | — | US | disclosed |
| US-20220162221-A1 | Imaging Agents | UCB Biopharma SRL (BE) | 2022-05-26 | — | — | US | disclosed |
| US-20220162221-A1 | Imaging Agents | UCB Biopharma SRL (BE) | 2022-05-26 | — | — | US | disclosed |
| EP-3717025-B1 | IMAGING AGENTS | UCB Biopharma SRL (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20200369675-A1 | Imaging Agents | UCB Biopharma SRL (BE) | 2020-11-26 | — | — | US | disclosed |
| EP-3717025-A1 | IMAGING AGENTS | UCB Biopharma SRL (BE) | 2020-10-07 | — | — | EP | disclosed |
| CN-110437161-A | A kind of preparation method of 5- methyl -6- chlorouracil | UNIV DALIAN | 2019-11-12 | — | — | CN | disclosed |
| CN-110437161-A | A kind of preparation method of 5- methyl -6- chlorouracil | UNIV DALIAN | 2019-11-12 | — | — | CN | disclosed |
| CN-110437161-A | A kind of preparation method of 5- methyl -6- chlorouracil | UNIV DALIAN | 2019-11-12 | — | — | CN | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-1553949-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1553949-A2 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040053952-A1 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014868-A2 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179716-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | PLA2G7, PLA2G4A, PLA2G1B | TYMP 100/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | TYMP 3164/4885 |
| US-20040053952-A1 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP13 | TYMP 31/4885 |
| US-20200369675-A1 | Imaging Agents | MPI, TMEM14C, NECTIN4 | TYMP 634/4885 |
| US-20220162221-A1 | Imaging Agents | MPI, TMEM14C, NECTIN4 | TYMP 634/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | TYMP 2616/4885 |
| US-20240343737-A1 | Imaging Agents | MPI, TMEM14C, NECTIN4 | TYMP 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.